FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2981620005> ?p ?o ?g. }

• W2981620005 endingPage "S768" @default.
• W2981620005 startingPage "S767" @default.
• W2981620005 abstract "Abstract Background Site-of-care decisions (e.g., admission vs. outpatient) in CABP management can be challenging for healthcare providers. Here we describe a post hoc analysis of adults with CABP managed as outpatients in the LEAP 2 double-blind, noninferiority, Phase 3 trial. Methods LEAP 2 compared the efficacy and safety of oral lefamulin (LEF) 600 mg every 12 hours for 5 days vs. oral moxifloxacin (MOX) 400 mg every 24 hours for 7 days in adults with PORT Risk Class II-IV. Descriptive statistics were generated to characterize demographics, baseline characteristics, efficacy, and safety outcomes in the subpopulation of outpatients in LEAP 2. Results Overall, 42% (310/736) of patients started treatment as outpatients (41% [151/368] LEF and 43% [159/368] MOX). Age, gender, and BMI were generally similar in both treatment groups. 44% (66/151) LEF and 40% (64/159) MOX outpatients had PORT Risk Class III or IV, and 21% in both groups (31/151 LEF and 34/159 MOX) had CURB-65 score 2 or 3. Comorbidities included smoking history (43% LEF vs. 34% MOX), hypertension (26% vs. 30%), COPD/asthma (14% vs. 18%), and diabetes mellitus (7% vs. 11%). Early clinical response (ECR) responder rates and investigator’s assessment of clinical response (IACR) success rates at the test of cure (TOC) visit were high and similar in both groups among all, PORT Risk Class III/IV, and CURB-65 score 2 or 3 outpatients (Table 1). In the PORT Risk Class III/IV subset, 86% LEF vs. 80% MOX patients were both an ECR responder and IACR success at TOC. In the CURB-65 score 2 or 3 subset, 87% LEF vs. 74% MOX patients were both an ECR responder and IACR success at TOC. Treatment-emergent adverse event (TEAE) rates were similar in both groups (Table 2). Consistent with overall study results, the difference between groups in related TEAEs was driven by gastrointestinal disorders (20% LEF vs. 5% MOX), specifically diarrhea (15% vs. 1%). Rates of TEAEs leading to discontinuation were low and similar in both groups. No LEF outpatient had an SAE or was admitted during the study, compared with 5 (3%) SAEs, including 2 deaths, in the MOX group. Conclusion These study data suggest that PORT Risk Class III or IV patients can be effectively managed as outpatients with 5 days of oral LEF as an alternative to fluoroquinolones for the treatment of CABP. Disclosures All authors: No reported disclosures." @default.
• W2981620005 created "2019-11-01" @default.
• W2981620005 creator A5004093056 @default.
• W2981620005 creator A5038464339 @default.
• W2981620005 creator A5045441720 @default.
• W2981620005 creator A5049148828 @default.
• W2981620005 creator A5054399119 @default.
• W2981620005 creator A5065282470 @default.
• W2981620005 creator A5086958262 @default.
• W2981620005 creator A5090212510 @default.
• W2981620005 date "2019-10-01" @default.
• W2981620005 modified "2023-09-23" @default.
• W2981620005 title "2245. Oral 5-Day Lefamulin for Outpatient Management of Pneumonia Outcomes Research Team (PORT) Risk Class III/IV Community-Acquired Bacterial Pneumonia (CABP): Post Hoc Analysis of the Lefamulin Evaluation Against Pneumonia (LEAP) 2 Phase 3 Study" @default.
• W2981620005 doi "https://doi.org/10.1093/ofid/ofz360.1923" @default.
• W2981620005 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6809828" @default.
• W2981620005 hasPublicationYear "2019" @default.
• W2981620005 type Work @default.
• W2981620005 sameAs 2981620005 @default.
• W2981620005 citedByCount "0" @default.
• W2981620005 crossrefType "journal-article" @default.
• W2981620005 hasAuthorship W2981620005A5004093056 @default.
• W2981620005 hasAuthorship W2981620005A5038464339 @default.
• W2981620005 hasAuthorship W2981620005A5045441720 @default.
• W2981620005 hasAuthorship W2981620005A5049148828 @default.
• W2981620005 hasAuthorship W2981620005A5054399119 @default.
• W2981620005 hasAuthorship W2981620005A5065282470 @default.
• W2981620005 hasAuthorship W2981620005A5086958262 @default.
• W2981620005 hasAuthorship W2981620005A5090212510 @default.
• W2981620005 hasBestOaLocation W29816200051 @default.
• W2981620005 hasConcept C126322002 @default.
• W2981620005 hasConcept C2776780178 @default.
• W2981620005 hasConcept C2777914695 @default.
• W2981620005 hasConcept C67761136 @default.
• W2981620005 hasConcept C71924100 @default.
• W2981620005 hasConceptScore W2981620005C126322002 @default.
• W2981620005 hasConceptScore W2981620005C2776780178 @default.
• W2981620005 hasConceptScore W2981620005C2777914695 @default.
• W2981620005 hasConceptScore W2981620005C67761136 @default.
• W2981620005 hasConceptScore W2981620005C71924100 @default.
• W2981620005 hasIssue "Supplement_2" @default.
• W2981620005 hasLocation W29816200051 @default.
• W2981620005 hasLocation W29816200052 @default.
• W2981620005 hasOpenAccess W2981620005 @default.
• W2981620005 hasPrimaryLocation W29816200051 @default.
• W2981620005 hasRelatedWork W1968950538 @default.
• W2981620005 hasRelatedWork W1989047233 @default.
• W2981620005 hasRelatedWork W2168449172 @default.
• W2981620005 hasRelatedWork W2362299873 @default.
• W2981620005 hasRelatedWork W2372071230 @default.
• W2981620005 hasRelatedWork W2399217294 @default.
• W2981620005 hasRelatedWork W2616191938 @default.
• W2981620005 hasRelatedWork W2895926441 @default.
• W2981620005 hasRelatedWork W2970099694 @default.
• W2981620005 hasRelatedWork W3174409575 @default.
• W2981620005 hasVolume "6" @default.
• W2981620005 isParatext "false" @default.
• W2981620005 isRetracted "false" @default.
• W2981620005 magId "2981620005" @default.
• W2981620005 workType "article" @default.